Managing Invasive Candidiasis: Key Strategies to Make a Difference
Released On
October 17, 2022
Expires On
October 19, 2023
Media Type
Internet
Completion Time
90 minutes
Specialty
Acute Care, Critical Care, Gastroenterology, Hematology-Oncology, Hospitalist, Infectious Disease, Medical Microbiology, Neonatology, Nephrology, Ophthalmology, Pathology, Primary Care, Pulmonology, Surgery, Urology
Topic(s)
Fungal Infections
Scroll to the Bottom of this Information to Begin this Course
Jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium.
This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.
Credit Available
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is directed to physicians with specialties in infectious diseases, pulmonary/critical care medicine, and pathology/laboratory medicine as well as other healthcare providers who care for patients at risk for or diagnosed with invasive candidiasis.
Program Overview
This activity, supported by the CDC, will demonstrate key strategies to optimize management of invasive candidiasis using an infographic-based approach.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe epidemiologic trends in invasive candidiasis
- Identify populations at risk for invasive candidiasis
- Employ appropriate diagnostic tests for invasive candidiasis
- Treat invasive candidiasis with the correct, pharmacologically optimized antifungal agent
Faculty
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM, CMQ
Professor of Medicine and Epidemiology
Vice-Chair of Medicine for Healthcare Quality
Chief, Division of Infectious Diseases
McGovern Medical School
Luis Ostrosky-Zeichner is a professor of medicine and epidemiology, the Vice-Chair of Medicine for Healthcare Quality, the director of the Laboratory of Mycology Research, and the Division Chief at the Division of Infectious Diseases of the McGovern Medical School (a part of UTHealth). He also serves as medical director for epidemiology and antimicrobial stewardship for Memorial Hermann Texas Medical Center and UT Physicians. He is also currently coordinating the CoVID-19 response for UTHealth and its affiliated hospitals and clinics.
Dr Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program.
Dr Ostrosky-Zeichner is a fellow of the American College of Physicians, the Infectious Diseases Society of America, the Society of Healthcare Epidemiology of America, and the Academy of the European Confederation of Medical Mycology. He is a Senior Editor for Journal of Antimicrobial Chemotherapy, as well as an editorial board member of Antimicrobial Agents and Chemotherapy and Clinical Infectious Diseases. He is Vice President of the Mycoses Study Group and Educational Consortium and a Vice-President of the International Immunocompromised Host Society. He is also a past chair of the Infectious Diseases Society of America Standards and Practice Guidelines Committee and has been a consultant to the US FDA and CDC. He has advanced training and experience in medical mycology, healthcare epidemiology, emerging infections, antimicrobial stewardship, general and transplant infectious diseases, and healthcare quality and has published over 175 peer-reviewed articles on those topics.
Peter G. Pappas, MD, FACP
William E. Dismukes Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Alabama School of Medicine
Birmingham, AL USA
Principal Investigator, Mycoses Study Group
Dr Peter G. Pappas is the William E. Dismukes Professor of Medicine in the Division of Infectious Diseases, and was the first Tinsley Harrison Clinical Scholar, Department of Medicine at the University of Alabama in Birmingham. Dr. Pappas attended medical school at the University of Alabama at Birmingham, graduating in 1978. He completed his residency in internal medicine, chief medical residency and infectious diseases fellowship at the University of Washington in Seattle. Following completion of his fellowship, he was on the clinical faculty at the University of North Carolina School of Medicine in Chapel Hill, NC, through its affiliated hospital in Wilmington, NC. In 1988, he joined the faculty at the University of Alabama in Birmingham School of Medicine, with a focus on HIV and transplant-associated opportunistic infections, especially the invasive mycoses. His main areas of interest have included the development of new therapies for fungal infections and understanding the epidemiology of candidiasis, the endemic mycoses, and cryptococcosis. He has performed numerous clinical trials in candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis, and histoplasmosis through his involvement with the National Institute of Allergy and Infectious Diseases’s Bacteriology and Mycology Study Group.
Dr Pappas is the Principal Investigator for the Mycoses Study Group Education and Research Consortium, an academic organization that performs multicenter trials, creates treatment guidelines for invasive mycoses, and coordinates CME training in the epidemiology, diagnosis, and treatment of invasive mycoses. As Director of the MSG, Dr Pappas has been instrumental in moving the consortium toward its current nonprofit status. He has also served as principal investigator of a national network of transplant centers, TRANSNET, in conjunction with the US Centers for Disease Control and Prevention and a consortium of industry co-sponsors to provide important epidemiologic and treatment information to transplant recipients who develop proven and probable invasive fungal infections. More recently, he served as co-PI of the Organ Transplant Infection Detection and Prevention Program (OTIP), a collaborative multicenter group funded by the CDC.
Physician Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM); Terranova Medica, LLC; and the Mycoses Study Group Education and Research Consortium (MSGERC), Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
- Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM, CMQ
-
- Research Support: Astellas, Gilead, Pfizer, Pulmocide, Scynexis
- Consultant: Cidara, F2G, Appili Therapeutics, Merck & Co, Inc
- Speaker: Pfizer, Gilead, F2G
- Peter G. Pappas, MD, FACP
-
- Research Support: Merck, Astellas, Scynexis, Cidara, Mayne
- Consultant: F2G, Cidara, Matinas
Instructions for Participation and Credit
- Register and complete all the sections.
- Complete all the online Posttest sections with a score of 75% or better.
- Once you complete the Posttest, a link to the evaluation on CME University will be unlocked.
- Upon completion of the evaluation, you will receive an immediate CME/CE Certificate to download and/or print for your files
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Postgraduate Institute for Medicine requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions please contact: tdavis@terranovamedica.com